Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03559010 · ClinicalTrials.gov registry record · Phase 3
A Study of Oral Contraception Under Simulated OTC Conditions
A Phase 3 study, sponsored by HRA Pharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 189
- Enrollment target
NCT03559010: Clinical Trial Phase 3 study, sponsored by HRA Pharma.
NCT03559010 is a Phase 3 study that was terminated before completion, run by HRA Pharma. The registered enrollment target is 189 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03559010, a Phase 3 study, was terminated before completion, sponsored by HRA Pharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 189 participants
- Enrollment target
Study Summary
This study is designed to assess whether consumers select and use norgestrel 0.075 mg, a progestin only pill for contraception, in a manner consistent with the OTC package directions in an Over-the-Counter (OTC)-like setting.
Primary Outcome
Proportion of self-selection population who make a correct selection decision regarding use of the product Study prematuraly discontinued No Self-selection endpoint calculations were made.
Interventions
- DRUG Norgestrel 0.075 mg tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 189 participants |
| Start Date | 2018-04-27 |
| Est. Completion | 2018-11-14 |
| Phase | Phase 3 |
Why NCT03559010 stopped before completion
NCT03559010 is an interventional study that assigns participants to a tested intervention. The registered 189 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 1 intervention - of which Norgestrel 0.075 mg tablets is the first listed.
NCT03559010 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03559010 about?
NCT03559010 is a clinical study titled "A Study of Oral Contraception Under Simulated OTC Conditions". This study is designed to assess whether consumers select and use norgestrel 0.075 mg, a progestin only pill for contraception, in a manner consistent with the OTC package directions in an Over-the-Counter (OTC)-like setting.
What is the current status of trial NCT03559010?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 189 participants. The study started on 2018-04-27. Estimated completion is 2018-11-14.
What interventions are being tested in trial NCT03559010?
The interventions under investigation include: Norgestrel 0.075 mg tablets (DRUG).
Who is sponsoring clinical trial NCT03559010?
This trial is sponsored by HRA Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03559010's enrollment target sits among peer trials
189 1408th of 2000 higher than 593 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02734537 · 189 participants · Phase 2
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- NCT05058651 · 189 participants · Phase 2
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
- NCT05673408 · 189 participants
NIBP Validation Study
- NCT05994209 · 189 participants · Phase 1
Testing the Feasibility and Acceptability of Social Media and Digital Therapeutics to Decrease Vaping Behaviors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI